Last reviewed · How we verify
Anplag
At a glance
| Generic name | Anplag |
|---|---|
| Also known as | UI03SPG300CT, Other Names:, DP-R202 : DP11002-3, Anplag : 0007-1, DP-R202 : DP11002-2 |
| Sponsor | Korea United Pharm. Inc. |
| Target | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Open-label, Single Dose, 3-Treatment, 3-Period Williams-Design to Assess the Pharmacokinetic Characteristics and Food Effect of Sarpogrelate HCl CR Tablets Compared With Sarpogrelate HCl (Phase 1)
- A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate in Efficacy and Safety of DP-R202 and Anplag Tab in Patients With Artery Occlusive Dise (Phase 3)
- A Randomized, Single-dose, 2-sequence, 2-period Crossover Study to Investigate the Food-effect Pharmacokinetics of Sarpogrelate HCl Controlled Release Tablet in Healthy Male Subjects (Phase 1)
- Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial (Phase 3)
- A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment (Phase 3)
- Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Progression of Coronary Artery Disease (Phase 4)
- Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (Phase 4)
- A Randomized, Open-label, Two-Sequence, Two-Period Crossover Study to Assess the Pharmacokinetic Characteristics of Sarpogrelate HCl Controlled Release Tablet Compared With Sarpogrelate HCl Immediate (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anplag CI brief — competitive landscape report
- Anplag updates RSS · CI watch RSS
- Korea United Pharm. Inc. portfolio CI